Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cellectar Biosciences, Inc.CLRB · Entity 7572 | Director | July 07, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cellectar Biosciences, Inc.
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2036-07-07 | Direct | 25,000 |
Reported balance
After 2026-07-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-07 · Grant · Acquired 25,000 · Balance 25,000 F1: This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 9, 2026 01:09 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001104659-26-082015 · tm2620095-7_4seq1.xml · derivative · entry 1 Chanan-Khan Asher · CIK 0001869837 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2036-07-07 F1 · derivative.exercise_date: This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:02 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001104659-25-014737 · tm256830-2_4seq1.xml · derivative · entry 1 Chanan-Khan Asher · CIK 0001869837 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-02-14 F1 · derivative.exercise_date: This option shall vest in full on February 14, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 21:00 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001104659-24-072875 · tm2417520-1_4seq1.xml · derivative · entry 1 Chanan-Khan Asher · CIK 0001869837 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-12-22 F1 · date: This option was contingently granted on December 22, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 14, 2024. F2 · derivative.exercise_date: This option shall vest in full on December 22, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 28, 2023 Filed Jun 28, 2023 22:24 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001104659-23-075937 · tm2320030-1_4seq1.xml · derivative · entry 1 Chanan-Khan Asher · CIK 0001869837 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,600 Underlying: Common Stock · 25,000 shares Expires 2033-06-28 F1 · derivative.exercise_date: This stock option shall vest in full on June 28, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 24, 2022 Filed Aug 1, 2022 22:00 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 7,800 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001104659-22-084832 · tm2222253-1_4seq1.xml · derivative · entry 1 Chanan-Khan Asher · CIK 0001869837 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2032-06-24 F1 · derivative.exercise_price: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. F1 · shares: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. F2 · derivative.exercise_date: This stock option shall vest in full on June 24, 2023, subject to the reporting person's continued service through the applicable vesting date. F1 · derivative.underlying_shares: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. F1 · balance_after: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:02 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 78,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001104659-21-088833 · tm2120855-2_4seq1.xml · derivative · entry 1 Chanan-Khan Asher · CIK 0001869837 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: Stock option vest in equal annual increments on June 30, 2022, June 30, 2023, and June 30, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.